Literature DB >> 1109798

Intercalative binding of ellipticine to DNA.

K W Kohn, M J Waring, D Glaubiger, C A Friedman.   

Abstract

Ellipticine (NSC 71795), a plant alkaloid with antitumor activity, is a weakly basic polycyclic molecule with dimensions similar to those of proflavin. Like proflavin, ellipticine exhibits hypocromic and bathochromic changes in absorption spectrum in the presence of DNA. It binds preferentially to helical DNA by intercalation, but the strength of binding is substantially greater than that of proflavin. The evidence for intercalation is based on effects on the sedimentation and viscosity of sheared DNA fragments, removal and reversal of the supercoiling of closed circular DNA, and electric dichroism measurements. The sedimentation and viscosity changes are quantitatively similar to those produced by proflavin. The unwinding angle on binding to supercoiled DNA is estimated to be 7.9 degrees, similar to that of proflavin. Electric dichroism shows the plane of the bound ellipticine molecule to be oriented parallel (plus or minus 7 degrees) to the plane of the bases in helical DNA. Ellipticine differs from proflavin in that it is uncharged at neutral pH and becomes protonated under mildly acid conditions. This feature may influence the intracellular distribution of the drug. Ellipticine bound to DNA is probably in its protonated form.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1109798

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

Review 1.  Strategies for the Optimization of Natural Leads to Anticancer Drugs or Drug Candidates.

Authors:  Zhiyan Xiao; Susan L Morris-Natschke; Kuo-Hsiung Lee
Journal:  Med Res Rev       Date:  2015-09-11       Impact factor: 12.944

2.  Thermotropic phase behavior of DPPC liposome systems in the presence of the anti-cancer agent 'Ellipticine'.

Authors:  Leide P Cavalcanti; Iris L Torriani
Journal:  Eur Biophys J       Date:  2006-06-23       Impact factor: 1.733

3.  Sequence-selective binding of an ellipticine derivative to DNA.

Authors:  C Bailly; C OhUigin; C Rivalle; E Bisagni; J P Hénichart; M J Waring
Journal:  Nucleic Acids Res       Date:  1990-11-11       Impact factor: 16.971

Review 4.  New cancer chemotherapy drugs in Europe.

Authors:  G Mathé; L M van Putten
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

5.  Lipid model membranes for drug interaction study.

Authors:  L P Cavalcanti; O Konovalov; I L Torriani
Journal:  Eur Biophys J       Date:  2006-04-06       Impact factor: 1.733

6.  Increased accessibility of bases in DNA upon binding of acridine orange.

Authors:  J Kapuscinski; Z Darzynkiewicz
Journal:  Nucleic Acids Res       Date:  1983-11-11       Impact factor: 16.971

7.  Regioselective arylation of ribose in adenosine and guanosine with the antitumor drug N2-methyl-9-hydroxyellipticinium acetate.

Authors:  J Bernadou; B Meunier; G Meunier; C Auclair; C Paoletti
Journal:  Proc Natl Acad Sci U S A       Date:  1984-03       Impact factor: 11.205

8.  The binding of echinomycin to deoxyribonucleic acid.

Authors:  S P Wakelin; M J Waring
Journal:  Biochem J       Date:  1976-09-01       Impact factor: 3.857

9.  Correlations between experimental chemotherapy in the murine glioma and effectiveness of clinical therapy regimens.

Authors:  V A Levin; C B Wilson
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

10.  Ellipticine increases the superhelical density of intracellular SV40 DNA by intercalation.

Authors:  Y Chu; M T Hsu
Journal:  Nucleic Acids Res       Date:  1992-08-11       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.